Trends in Diabetic Retinal Disease Among Diabetes Patients: Implications for Insurance
A recent study analyzing insurance claims data from Optum's Clinformatics Data Mart reveals significant trends in diabetic retinal disease (DRD) among patients with diabetes in the United States. The data encompasses individuals covered under commercial insurance and Medicare Advantage plans. The research evaluated the prevalence and incidence of DRD among 3,682,484 diabetic patients, including 101,579 with type 1 diabetes and 3,580,905 with type 2 diabetes. Additionally, the study explored secondary outcomes like vision-threatening diabetic retinal disease (VTDR), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR).
The findings indicate a rising prevalence of DRD among both type 1 and type 2 diabetes patients from 2016 to 2021. Specifically, prevalence in type 1 diabetes increased from 25% to 34%, and in type 2 diabetes from 11% to 21%. Although individuals with type 1 diabetes consistently showed higher prevalence rates compared to those with type 2, the difference narrowed over time. In terms of severe disease, VTDR prevalence rose from 12% to 17% in type 1 diabetes and from 4% to 6% in type 2 diabetes. Similarly, DME and PDR prevalence gained traction in both groups.
The study also highlighted incidence patterns, showing a decline in overall DRD incidence for type 1 diabetes from 55.1 cases per 1,000 person-years in 2016 to 39.2 in 2022. Conversely, type 2 diabetes incidence fluctuated between 31.6 and 38.5 cases per 1,000 person-years, reaching 35.5 in 2022. This convergence in incidence rates indicates that by 2022, the incidence gap between type 1 and type 2 diabetes patients had narrowed. However, disparities persisted in subtypes such as VTDR, DME, and PDR, with type 1 diabetes showcasing consistently higher rates.
Lead researcher Sonny Caplash of the University of Pennsylvania observed that despite a reduction in incidence rates, overall DRD prevalence remained higher in type 1 diabetes. The study suggests this trend might reflect an increasing demographic of diabetes patients and advancements in diabetes care, which extend patient longevity. It's crucial to mention that the study faced limitations, including reliance on administrative claims lacking clinical detail and the potential impacts from altered healthcare utilization during the COVID-19 pandemic.
These findings underscore the ongoing challenges and advancements in managing diabetic complications within the insurance industry, stressing the continuous need for innovation in care and management strategies for diabetes patients. This highlights an opportunity for providers and payers to enhance care models, integrating risk management and regulatory compliance requirements to further improve patient outcomes.